News Roche cuts price of HIV blindness drug HannahBlake 0 Comment Roche has announced it is increasing access to a key drug to treat blindness in patients with HIV Share X Roche cuts price of HIV blindness drug https://pharmaphorum.com/news/roche-cuts-price-of-hiv-blindness-drug/
News FDA pushes review of GSK’s diabetes drug back HannahBlake 0 Comment GlaxoSmithKline’s approval review date for its diabetes drug has been pushed back by three months by the US Share X FDA pushes review of GSK’s diabetes drug back https://pharmaphorum.com/news/fda-pushes-review-of-gsk-s-diabetes-drug-back/
News Sanofi had a “difficult” second quarter, says CEO HannahBlake 0 Comment Sanofi’s sales slumped in the second quarter of 2013 to €8,003 million – a decrease of nearly 10% Share X Sanofi had a “difficult” second quarter, says CEO https://pharmaphorum.com/news/sanofi-had-a-difficult-second-quarter-says-ceo/
News Actelion to acquire Ceptaris for $250m if rare disease drug approved HannahBlake 0 Comment Switzerland-based biopharma company, Actelion Ltd has entered an agreement to acquire privately-held US speciality pharma company, Ceptaris Therapeutics Share X Actelion to acquire Ceptaris for $250m if rare disease drug approved https://pharmaphorum.com/news/actelion-to-acquire-ceptaris-for-250m-if-rare-disease-drug-approved/
News AZ pleased with Q2 progress, despite revenue loss HannahBlake 0 Comment AstraZeneca has reported a 4% decrease in revenue in the second quarter of 2013 following a recent loss Share X AZ pleased with Q2 progress, despite revenue loss https://pharmaphorum.com/news/az-pleased-with-q2-progress-despite-revenue-loss/
News Better-than-expected Q2 for Amgen HannahBlake 0 Comment Amgen has reported higher-than-expected financial results for the second quarter of 2013. Total revenues increased 5% to US Share X Better-than-expected Q2 for Amgen https://pharmaphorum.com/news/better-than-expected-q2-for-amgen/
News Pfizer agrees to $491M settlement in off-label marketing case Rebecca 0 Comment Pfizer has agreed to pay a $491m settlement fee in criminal and civil penalties following allegations of off-label Share X Pfizer agrees to $491M settlement in off-label marketing case https://pharmaphorum.com/news/pfizer-agrees-to-491m-settlement-in-off-label-marketing-case/
News BMS, Samsung BioLogics enter 10-year manufacturing deal HannahBlake 0 Comment Bristol-Myers Squibb has announced a 10-year manufacturing agreement with Korea-based Samsung BioLogics. Financial terms were not disclosed. Under Share X BMS, Samsung BioLogics enter 10-year manufacturing deal https://pharmaphorum.com/news/bms-samsung-biologics-enter-10-year-manufacturing-deal/
News Pfizer reports Q2 results; internal company split HannahBlake 0 Comment Pfizer has reported its financial results for the second quarter of 2013. The global pharma company’s revenue fell Share X Pfizer reports Q2 results; internal company split https://pharmaphorum.com/news/pfizer-reports-q2-results-internal-company-split/
